Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Immune Checkpoint Inhibitors & Immune-Related Adverse Events

Priya Chokshi, MD, Roberta Seidman, MD, Noah Levit, PhD, MD, & Steven E. Carsons, MD  |  Issue: September 2018  |  September 20, 2018

At this point, rheumatology was consulted to rule out myositis. The exam was significant for decreased strength of hip flexion and knee extension (2/5); proximal girdle weakness of her upper and lower extremities bilaterally; ptosis of the right eyelid; stridor; pooling of upper airway secretions in the posterior pharynx; coarse breath sounds in both lungs; and multiple, bullous, 0.5–1.5 cm, round, erythematous plaques on both distal lower extremities. Pulse oximetry was 90% at rest, and the patient was started on oxygen therapy.

A chest X-ray showed right basilar atelectasis and a small pleural effusion. On pulmonary evaluation, a computed tomography (CT) scan of the lung did not show interstitial lung disease, alveolitis or pulmonary embolus, but did show mucous collections in the distal airway. Ear, nose and throat evaluation suggested laryngeal and vocal cord edema contributing to stridor. A modified barium swallow was concerning for oropharyngeal dysphagia, and a nasogastric tube had to be inserted for enteral nutrition.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Her aldolase was elevated at 62 u/L (upper limit of normal [ULN] <7.5 units/liter). Autoimmune serologies and specific markers of myositis were negative—including ANA, anti-dsdna, anti-smith, anti-RNP, SSA/SSB, anti-Scl, anti-striational, anti-acetylcholine receptor binding (Ach-Ab), HMG Co-A reductase, anti-Jo, anti-SRP, anti-Mi2 and myositis panel (PL-7, PL-12, MI-2, KU, EJ, OJ). A thyroid panel and antibodies were normal. CA125 markers and CTs of her chest, abdomen and pelvis were negative for recurrence of ovarian cancer. Consultations with the gynecology and oncology departments deemed the cancer in remission.

The dermatologist performed a punch biopsy of the pretibial rash. It showed perivascular inflammatory cell infiltrate with lymphocytes, histiocytes, rare eosinophils, a few plasma cells and neutrophils. The infiltrate subtly obscured the dermo-epidermal junction where there was vacuolar alteration and necrotic keratinocytes within the epidermis. Signs of focal ulceration and subepidermal clefting were evident. A PAS stain was negative for hyphae or basement membrane zone thickening. We were concerned about a drug eruption, manifestation of collagen vascular disease or early autoimmune vesiculobullous disorder.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Nerve conduction studies and electromyography were performed in the right upper and right lower extremities and were consistent with myopathic change of the muscles without suggestion of large fiber polyneuropathy or necrosis. Specifically, there was low amplitude of the right sural sensory response and right tibial motor response and absence of right peroneal F right tibial H reflexes. Skeletal muscle biopsy of the left quadriceps revealed immune-mediated myopathic disorder, identified by a positive HLA Class I immunohistochemistry study, with focal myofiber necrosis/regeneration, mild inflammation and type 2 myofiber atrophy. The findings were consistent with an immune-mediated (inflammatory) myopathy, subtype not specifically identified (see Figure 2).

Page: 1 2 3 4 5 6 7 8 9 10 | Single Page
Share: 

Filed under:ConditionsDrug UpdatesMyositisOther Rheumatic Conditions Tagged with:immune-related adverse eventsirAEsmyositisnivolumab

Related Articles
    Lightspring/shutterstock.com

    The Immune Checkpoint Inhibitors Unleashed to Fight Cancer

    May 17, 2017

    A 53-year-old female presented to the clinic for severe polyarticular joint pain and was found to have a seronegative inflammatory arthritis. Six months before, she had completed 10 months of treatment for stage IV metastatic melanoma with the immune checkpoint inhibitors, nivolumab and ipilimumab, achieving complete remission of her cancer. She said that throughout her…

    Alpha Tauri 3D Graphics / shutterstock.com

    Rheumatic Complications from Immune Checkpoint Inhibitors

    December 16, 2021

    Immune checkpoint inhibitors (ICIs), such as anti-programmed cell-death 1/programmed death-ligand 1 (anti-PD-1/PD-L1) or anti-CTL-associated protein (anti-CTLA-4), have dramatically changed the treatment of advanced cancers over the past decade. ICIs block T cell inhibition, thus increasing the anti-tumor immune response. ICIs are used not only for metastatic cancer, but also as adjuvant treatment for some stage…

    Nivolumab-Induced Arthritis

    October 18, 2018

    Immune checkpoint inhibitors (ICIs) are increasingly used to treat a variety of malignancies, leading to better cancer treatment outcomes and patient survival. However, the emergence of autoimmunity has been a major adverse event resulting from ICI use. Below, we describe a patient who experienced a flare of preexisting psoriasis and new-onset severe psoriatic arthritis after…

    ACR Convergence graphic

    Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors

    December 4, 2020

    Immune checkpoint inhibitors effectively treat malignancy in ways that were not possible just a few years ago, but immune-related adverse events are a potential side effect.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences